<DOC>
	<DOC>NCT01069601</DOC>
	<brief_summary>The trial investigates the efficacy of the adjuvanted H1N1 influenza vaccine Focetria(R) in immunocompromised adults who have undergone solid organ or bone marrow transplantation. It is expected that when administered twice the vaccine fulfills all serological efficacy criteria required for the elderly population age 60 years and older.</brief_summary>
	<brief_title>H1N1sw Vaccine in Adult Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Adult subjects 1860 years of age who have undergone prior renal, cardiac, liver, lung, or bone marrow transplantation for any reason, more than 3 months prior to enrolment Patients able to visit the outpatient clinic with a life expectancy of at least one year Patients who receive any immunosuppressive treatment currently taken to prevent organ rejection Individuals who received any vaccine within 30 days prior to study entry Individuals who received a H1N1 vaccination less than 6 months prior to the study Influenza diagnosed by a physician within 4 months prior to the study start Pregnant or lactating females History of an anaphylactic (i.e. lifethreatening) reaction to any of the components of the vaccines, including egg and chicken proteins, ovalbumin, kanamycin and neomycin sulphate, formaldehyde and cetyltrimethylammonium bromide (CTAB)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>solid organ transplantation</keyword>
	<keyword>bone marrow transplantation</keyword>
	<keyword>adults</keyword>
	<keyword>adults with solid organ transplantation</keyword>
	<keyword>adults with bone marrow transplantation</keyword>
</DOC>